LNTH Lantheus Holdings, Inc.
In Vitro & In Vivo Diagnostic Substances · Nasdaq · SEC EDGAR official
Market Value*
$4.27B
Revenue (FY)
$1.54B 2025-12-31
Net Income (FY)
$233.56M
P/E (float-based)
18.3
In Vitro & In Vivo Diagnostic Substances · Nasdaq · SEC EDGAR official